NCT07058662招募中1 期
A Phase 1/2, Open-label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
Belief BioMed (Beijing) Co., Ltd2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2025年7月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Incidence of dose limiting toxicity (DLT) events
研究概览
简要总结
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.
详细描述
This is a single-arm, open-label study to evaluate the safety, tolerability, efficacy, pharmacokinetic, pharmacodynamic, and immune response of BBM-D101 within 52 weeks after a single intravenous infusion in DMD boys, as well as the long-term safety and efficacy of BBM-D101 for up to 5 years post infusion.
BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 9 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •The Participants and/or his legal guardian must fully understand the purpose, nature, methods, and potential risks of the study, and sign a written informed consent form.
- •Ambulatory male subjects aged 4 years and above but under 9 years (4 years ≤ age < 9 years).
- •Any mutation in the DMD gene confirmed by genetic testing
- •Serum creatine kinase (CK) during the screening period meets the study requirements.
- •Receiving stable, standard-dose glucocorticoids before screening.
- •The subject's AAV capsid antibodies meet the clinical trial requirements.
- •Able to cooperate with motor function assessment, MRI, and muscle biopsy as required by the study.
- •Laboratory test results during the screening period and at baseline meet the standards.
- •The subject and/or his legal guardian must fully understand the study procedures, be willing to actively cooperate, commit to high compliance with the protocol, and ensure that the subject attends all scheduled visits.
排除标准
- •Positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 1000 U/mL, hepatitis C virus ribonucleic acid (HCV-RNA) positive, human immunodeficiency virus (HIV) positive, or positive for Treponema pallidum antibodies.
- •Currently receiving antiviral therapy for hepatitis B, hepatitis C, HIV, etc.
- •The investigator deems the subject has severe behavioral or cognitive disorders that may hinder participation in this study.
- •Poorly controlled asthma, or Duchenne Muscular Dystrophy (DMD) leading to significant decline in lung function, or recurrent infectious pneumonia that the investigator considers may affect respiratory function.
- •Left ventricular ejection fraction (LVEF) < 50% or New York Heart Association (NYHA) cardiac function class ≥ III.
- •Severe or persistent arrhythmias (such as atrial fibrillation, frequent ventricular premature beats, ventricular bigeminy, ventricular trigeminy, severe bundle branch block, etc.), and congenital heart disease that is evaluated by the investigator as unsuitable for participation in this study.
- •Any changes in preventive/cardiomyopathy treatment (initiation of treatment, drug changes, dosing regimen changes, treatment interruption, termination, or restart) within 1 month before the infusion of the study drug.
- •History of liver diseases such as portal hypertension, splenomegaly, hepatic encephalopathy, liver fibrosis ≥ stage 3, or hepatic nodules/cysts found by ultrasound during screening, or elevated alpha-fetoprotein with clinical significance as determined by the investigator.
- •Severe infection (such as pneumonia, pyelonephritis, or meningitis) within 4 weeks before the treatment visit (enrollment may be postponed).
- •History of gene therapy or cell therapy (such as stem cell transplantation).
- •History of or current presence of autoimmune diseases, severe renal, gastrointestinal, neurological, or coagulation disorders, malignant tumors, or other diseases.
- •Other diseases that the investigator deems unsuitable for participation in this study.
结局指标
主要结局
Incidence of dose limiting toxicity (DLT) events
时间窗: Within 12 weeks
To evaluate the rate of incidence of DLT events determined by the Safety Data Review Committee (SRC) in DLT observation period after BBM-D101 infusion.
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: Within 12 weeks
To evaluate the safety of BBM-D101 by AEs and SAEs.
次要结局
- Changes from baseline in BBM-D101 therapeutic protein level of muscle biopsy samples(Within 52 weeks)
- Changes from baseline in serum Creatine Kinase (CK) level(Within 52 weeks)
- Changes from baseline in the time to ascend time to rise (TTR) without assistance(Within 52 weeks)
- Changes from baseline in the time to ascend 10-meter walk/run test (10MWR) without assistance(Within 52 weeks)
- Changes from baseline in the time to ascend 4 steps (4-stair climb, 4-SC) without assistance.(Within 52 weeks)
- Changes from baseline in the North Star Ambulatory Assessment (NSAA).(Within 52 weeks)
- Changes from baseline in the TTR， 10MWR , 4-SC，NSAA.(Within 5 years)
- Incidence of AEs and SAEs.(Within 5 years)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
BPB-101 in Subjects With Metastatic or Locally Advanced Solid TumorsSolid TumorNCT05869240Betta Pharmaceuticals Co., Ltd.388
招募中
早期 1 期
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)NCT06641895Shanghai Jiao Tong University School of Medicine6
招募中
2 期
BMB-101 in Absence Epilepsy and DEEAbsence EpilepsyJeavons SyndromeDravet SyndromeLennox Gastaut SyndromeNCT06401538Bright Minds Biosciences Pty Ltd20
已完成
2 期
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05093855Staidson (Beijing) Biopharmaceuticals Co., Ltd41
招募中
2 期
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06498986Sichuan Baili Pharmaceutical Co., Ltd.40